Note: Neon Therapeutics's revenues are gauged from an analysis of company filings.
Neon Therapeutics has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.
December 13, 2017
Complete list of funding rounds and total amounts in the Company Report
Neon Therapeutics's Income Statement (based on Industry Averages)
$ Millions (Industry Average)
Neon Therapeutics Revenue (Sales)
Cost of Goods Sold
Salaries and wages
Other Operating Expenses
Total Operating Expenses
EBIT (Earnings Before Interest and Taxes)
Trademark applications show the products and services that Neon Therapeutics is developing and marketing.
Neon Therapeutics's new tradmarks suggest it is investing in R&D and marketing, while expanding into new products or markets.
Trademarks may include brand names, product names, logos and slogans.
RECON BIOINFORMATICS ENGINE Conducting early evaluations in the field of new pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; pharmaceutical product development services; pharmaceutical product evaluation services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceuticals for the treatment of cancer; research and development of vaccines and medicines; technical research in the field of pharmaceutical studies; development of platform technology, namely, cancer immunotherapy platforms for manufacturing therapeutics; conducting clinical trials for others in the field of pharmaceuticals for the treatment and prevention of cancer; and consulting services for others in the field of design, planning, and implementation of clinical trials
NEO-STIM Pharmaceuticals, namely, immunotherapies; oncological preparations, namely, pharmaceutical products for the detection, prevention, and treatment of cancer; anti-cancer preparations; biological preparations for the treatment of cancer and oncological conditions; pharmaceutical products for the prevention and treatment of cancer and oncological conditions; synthetic peptides for the treatment of cancer and oncological conditions; and vaccine preparations; medical assays
NEON THERAPEUTICS Pharmaceuticals, namely, immunotherapies; oncological preparations, namely, pharmaceutical products for the detection, prevention, and treatment of cancer; anti-cancer preparations; biological preparations for the treatment of cancer and oncological conditions; pharmaceutical products for the prevention and treatment of cancer and oncological conditions; synthetic peptides for the treatment of cancer and oncological conditions; and vaccine preparations
Determine whether Neon Therapeutics grew or shrank during the last recession. This is useful in estimating the
financial strength and credit risk of the company.
Compare how recession-proof Neon Therapeutics is relative to the industry overall.
While a new recession may strike a particular industry, measuring the
industry and company's robustness during the last recession estimates its ability to weather future recessions.
Market Share of Competition: Neon Therapeutics vs. Largest Competitors
A competitive analysis shows these companies are in the same general field as Neon Therapeutics, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Neon Therapeutics.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Neon Therapeutics and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.